Ibrance is indicated for the treatment of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant in patients with disease progression following endocrine therapy.1

Established safety profile


​​​​​​​
Overview Adverse events in PALOMA-3 Adverse events in PALOMA-3
AEs (≥10%) reported in PALOMA-3 (safety population)2
​​​​​​​

​​​​​​​Adapted from Cristofanilli M, et al. 2016.2
​​​​​​​

Grading according to CTCAE 4.0 and MedDRA 18.0. Data cut-off date: March 16, 2015. Data are n (%) unless otherwise specified.2
*One other case of pleural effusion that was not graded also occurred in the IBRANCE + FUL group. Reported causes of death were neutropenic sepsis, multiple organ failure, and disease progression based on latest site follow-up information.


AE = adverse event; CTCAE = Common Terminology Criteria for Adverse Events; FUL = fulvestrant;
MedDRA = Medical Dictionary for Regulatory Activity; n = number of patients;  PLA = placebo.​​​​​​​
​​​​​​​

References

  1. IBRANCE® (Palbociclib) Prescribing Information. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=12240. Accessed September 17, 2021.
  2. Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439.

Support and Services


Learn more ► 
Learn more ► 
Learn more ► 
All rights reserved. Date of preparation: June 2020 PP-IBR-GLB-0254

​​​​​​​Intended for Healthcare Professionals only.

© 2021 Pfizer Pte Ltd. All rights reserved.


The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.